metallic taste tirzepatide Mounjaro Sweet in Mouth: Causes and Management You’ll never guess what a

[ Links ] 44

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE

As with all fat reduction treatments it is not a substitute for a healthy lifestyle, including proper diet and exercise, and results will not be maintained unless these factors are also considered

This once-weekly injectable medication is recommended for adults with type 2 diabetes to improve glycemic control and for individuals struggling with obesity or overweight conditions to aid in long-term weight management

Requires concentration change or split injection